


MAY 2018



RHENMAN HEALTHCARE EQUITY L/S

OUTSTANDING LONG-TERM PERFORMANCE IN A COMPLEX MARKET

- Annualised return of 21 % (net) since inception.
- Over 20 years managing successful healthcare funds.
- World renowned industry professionals each with over 30 years experience actively involved through the Scientific Advisory Board.
- Unquestionable alpha generation. outperforming all relevant indices and top quartile in all relevant rankings.
- Long term investment horizon:
 - Diversified across subsectors. company size and geographies to lower volatility.
 - Active trading around holdings.
 - Predominantly cash flow positive companies.
 - Typically investing post approval, mitigating event risk.

MONTHLY UPDATE

The positive stock market performance we saw in April continued into May, albeit with wide variations between different markets. In particular, American growth companies rose while European value companies fell. Exchange rate movements also remained large, with a further strengthening of the US dollar and a major recovery of the Swedish krona from its weak performance in April. Depending on the currency, there were significant differences in returns during the month with the world index unchanged in USD, and up by 0.5 percent in SEK, while in EUR it saw an increase of more than 3 percent.

With the close of the first-quarter earnings season for most major corporations, the market's focus turned to macro events. Economic data and political events, especially in Europe, came to play a large role in investors' perception of markets during the month. The long-awaited meeting between President Trump and North Korea's Kim Jong-Un, which after its first announcement was

cancelled and then rescheduled for June 12, attracted plenty of interest. Meanwhile developments in Europe were brought into even sharper focus. In mid-May, the winners of the Italian elections, the Five Star Movement and Lega Nord, nominated eurosceptic Paolo Savona as finance minister. The news was received with great concern by the financial markets and Italian interest rates rose sharply while the Milan Stock Exchange fell.

At the same time, the conservative prime minister of Spain, Mariano Rajoy, was forced to resign following corruption scandals within his party, the Partido Popular. This had a negative impact on Spanish interest rates and equities. Currency turmoil in Turkey, where Spanish banks are major lenders, fueled the unrest. Even Latin America, with yet another currency crisis in Argentina and a massive transportation strike in Brazil, adversely affected investors' willingness to take risks.

Towards the end of May, the Trump administration made a

Continued on the next page ➤

statement that the steel and aluminum tariffs originally announced in March despite negotiations would be imposed starting in June, renewing fears of an escalating trade war.

All in all, this led to widespread concern over economic developments in Europe and Latin America, with massive outflows of capital from these regions to the benefit of reallocation to the United States. Sector-wise, the upside was dominated by technology, which rose worldwide by approximately 7 percent, while banks fell by just over 3 percent. Healthcare was up approximately 4 percent.

FUND PERFORMANCE

Measured in its main share class IC1 (EUR), the fund rose by 6.26 percent in May.

Despite significant setbacks for two of the fund's holdings, the fund showed strong performance during the month. The Trump administration's launch of initiatives to improve healthcare and the availability of drugs for American patients was well received by the financial markets. The healthcare sector, led by biotechnology, reacted with considerable gains of 4.1 percent (MSCI World HC) and 8.5 percent (NBI). Among the month's top contributors were Horizon Pharma, Abiomed and Intra Cellular Therapies. The worst contributors were Faron Pharmaceuticals, Esperion Therapeutics and Genmab.

Horizon Pharma, a US specialty pharma company, has systematically shifted its focus over the past year from primary care drugs to specialty drugs. Its first-quarter interim report released in May confirmed that this strategy has been successful. Since hitting a low in May of last year, its share price has gone up nearly 70 percent.

Abiomed is a US medical technology company. The company's product Impella, a minimally invasive cardiac pump, is a world leader in improving blood circulation when the patient's own cardiac function is reduced for various reasons. The technology behind Impella is unique and its area of application is comprehensive, which means a continued source of untapped growth potential for the product. A strong interim report in which the company exhibited strong sales growth had a highly positive impact on its share price,

which has doubled in value so far this year. Abiomed is thus the fund's top contributor since the start of the year.


The US research company Intra-Cellular Therapies is expected in the near future to apply for FDA approval for its drug candidate lumateperone for the treatment of schizophrenia. The effects of lumateperone are also being studied in the indication of bipolar depression, and results from a phase III trial in this indication are expected during the second half of 2018. The positive outlook for lumateperone has led to positive share price performance in recent weeks.

Faron Pharmaceuticals is a Finnish research company. The company's drug candidate Traumakine was developed to treat so-called shock lung, an acute and life-threatening condition. It had a major setback in May because results from a phase III trial showed that the product had no clinical effect. Following the negative trial results, the share price fell by nearly 90 percent. The company is currently evaluating possible reasons for the major discrepancies in results compared with its phase II trials.

Esperion Therapeutics is a US research company that is developing a new drug in tablet form for the treatment of hypercholesterolemia. Results from two phase III trials were presented during the period. The results confirmed the effect on lowering blood fat seen in previous trials, but an imbalance in the side-effect profile compared with the control group created uncertainty among investors regarding the likelihood of getting the product approved by the authorities. This, in turn, put pressure on the valuation of the company, which saw its share price nearly halved during the period.

Genmab is a Danish biotech company that develops antibodies for the treatment of cancer and inflammatory diseases. The company's product Darzalex is approved for the treatment of the blood cancer multiple myeloma. Together with its partner Janssen Biotech, Genmab is also evaluating the product in several different tumor types as well as in a combination therapy with so-called PD-1 inhibitors. In May, Genmab announced that it would discontinue a phase I/II trial of Darzalex in combination with Roche's

FUND PERFORMANCE - IC1 (EUR)



MAY 2018

| SHARE CLASS | NAV | MONTHLY RETURN | YTD 2018 | SINCE INCEPTION ¹ |
|----------------------------------|--------|----------------|----------|------------------------------|
| IC1 (EUR) | 556.39 | 6.26% | 11.04% | 456.39% |
| IC3 (EUR) | 647.20 | 7.01% | 12.48% | 547.20% |
| IC2 (SEK) | 411.90 | 4.14% | 15.60% | 311.90% |
| ID1 (SEK) | 315.52 | 4.11% | 9.02% | 215.52% |
| IC1 (USD) | 145.38 | 3.69% | 8.54% | 45.38% |
| IC2 (USD) | 195.95 | 3.72% | 8.79% | 95.95% |
| RC1 (EUR) | 487.65 | 6.23% | 10.95% | 387.65% |
| RC1 (SEK) | 501.86 | 4.07% | 15.14% | 401.86% |
| RC2 (SEK) | 522.72 | 4.10% | 15.44% | 422.72% |
| Benchmark (>0), Euribor 3M (EUR) | 103.16 | 0.00% | -0.11% | 3.16% |


Notes: ¹ Please find launch date information on page 4 and 6.

Tecentrique for the treatment of lung cancer because they did not observe any increased effect but rather a slight trend towards increased mortality in patients treated with the combination and their share price dropped sharply.

FORECAST

The White House press conference on prescription drug prices on May 11 revealed itself to be the starting point for a better stock market mood for the healthcare sector in general, and for biotechnology in particular. The measures proposed were well in line with what was presented in the Trump administration's budget proposal earlier this year, and expectations were set that similar proposals would be made going forward. Several of the proposals are industry-friendly by their very nature, such as the improvement of prescription drug insurance. The positive reaction was, however, due mainly to the absence of any unexpected proposals for price controls or central contracts. So, for the moment, the industry can catch its breath, submit comments in an upcoming consultation and then wait for the details of the new regulations from the Centers for Medicare & Medicaid Services (CMS). Further investigations will take place, and the current administration might also try to influence Congress to legislate on certain issues. Many of these efforts, of course, are planned for the future. Given that all of this work will take time to investigate and implement, and that it is based on successive changes to the current structures, the sector looks increasingly attractive relative to other sectors, not least in light of potentially weaker economic development over the course of 2019. ■

CURRENCY EXPOSURE²



EXPOSURE⁴

| | |
|-------|-------|
| Long | 154 % |
| Short | 18 % |
| Gross | 172 % |
| Net | 136 % |

RISK (IC1 EUR)

| | |
|---------------------------------|---------|
| Value at risk ⁵ | 1.94 % |
| Standard Deviation ⁶ | 19.90 % |
| Sharpe Ratio ⁶ | 1.05 |

SHARE CLASS CHARACTERISTICS – INSTITUTIONAL SHARE CLASSES (ONLY INSTITUTIONAL INVESTORS)⁸

| | MINIMUM INVESTMENT | MGT. FEE | PERF. FEE | ISIN NUMBER | BLOOMBERG TICKER | LIPPER REUTERS | TELEKURS |
|-----------|--------------------|----------|-----------|--------------|------------------|----------------|----------|
| IC1 (EUR) | 250,000 | 1.50 % | 20 % | LU0417598108 | RHLEIC1 LX | 65147588 | 10034579 |
| IC3 (EUR) | 5,000,000 | 1.50 % | 10 % | LU0434614789 | RHHIC3 LX | 68014068 | 10283697 |
| IC2 (SEK) | 50,000,000 | 1.00 % | 20 % | LU0417598793 | RHHIC2S LX | 68204997 | 20323930 |
| ID1 (SEK) | 100,000 | 1.50 % | 20 % | LU0417599098 | RHHCID1 LX | 68153820 | 18491109 |
| IC1 (USD) | 300,000 | 1.50 % | 20 % | LU0417598280 | RHUIC1A LX | 68305812 | 26812813 |
| IC2 (USD) | 6,000,000 | 1.00 % | 20 % | LU0417598520 | RHUIC2U LX | 68265724 | 24456000 |

SHARE CLASS CHARACTERISTICS – RETAIL SHARE CLASSES (ALSO OPEN TO INSTITUTIONAL INVESTORS)⁸

| | | | | | | | |
|-----------|-----------|--------|------|--------------|------------|----------|----------|
| RC1 (EUR) | 2,500 | 2.00 % | 20 % | LU0417597555 | RHLERC1 LX | 65147589 | 10034567 |
| RC1 (SEK) | 500 | 2.00 % | 20 % | LU0417597712 | RHLSRC1 LX | 68014067 | 10239523 |
| RC2 (SEK) | 2,500,000 | 1.50 % | 20 % | LU0417598017 | RHLSRC2 LX | 68015239 | 10239528 |

Notes: ² As a percentage of the market value of the long and short positions (excluding cash positions). ³ Number of long equity positions (excluding any ETFs). ⁴ The exposure is adjusted for net fund flow at month end. ⁵ For holdings at month end (95 % conf. int. 250 days history). ⁶ Standard deviation and Sharpe ratio are annualized. ⁷ The AUM is adjusted for net fund flow at month end.

⁸ Administrative fees are charged in addition to the fees above. Further information is available in the KIID as well as the prospectus (part B. A14-18).

FUND CHARACTERISTICS

KIID AND PROSPECTUS (WEBPAGE)

<http://fundinfo.sebfundservices.lu/RhenmanPartnersFund/>

AIFM / MANAGEMENT COMPANY

SEB Fund Services S.A.

PRIME BROKER

Skandinaviska Enskilda Banken AB (publ)

INVESTABLE CURRENCIES

Euro (EUR) / Swedish Krona (SEK) / US Dollar (USD)

DEPOSITARY AND PAYING AGENT

Skandinaviska Enskilda Banken S.A.

TARGET FUND SIZE

EUR 1bn (hard close)

RETURN TARGET

Annualised net returns in excess of 12% over time

AUDITOR

PricewaterhouseCoopers (PwC)

LEGAL STRUCTURE

AIF / FCP (Fonds Commun de Placement) under Part II of the Luxembourg Law on Investment Funds

SUBSCRIPTION / REDEMPTION

Monthly

PORTFOLIO MANAGER

Rhenman & Partners Asset Management AB

MINIMUM TOP UP

No minimum

INVESTMENT TEAM

Henrik Rhenman & Susanna Urdmark

NOTICE PERIOD

3 working days

HURDLE RATE

Euribor 90D (high-water mark)

PORTFOLIO CONSTRUCTION³

| PYRAMID LEVEL | POSITION SIZE | NO. |
|----------------------|---------------|-----|
| High conviction | 3 %-10 % | 14 |
| Core holdings | 1 %-3 % | 53 |
| Fractional positions | 0.5 %-1 % | 17 |
| Candidate holdings | 0 %-0.5 % | 23 |

AUM⁷

| |
|----------|
| Fund: |
| EUR 614m |
| USD 716m |
| Firm: |
| EUR 625m |

LARGEST LONG POSITIONS

| |
|---------------------------|
| 1 Horizon Pharma Plc |
| 2 Jazz Pharmaceuticals |
| 3 United Health Group Inc |
| 4 Bristol Myers Squibb Co |
| 5 Humana Inc |

HISTORICAL RETURNS AND NAVS

| IC1 (EUR) NAV | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |
| 2009 | | | | | | 100.75 | 105.19 | 107.47 | 107.83 | 100.99 | 105.70 | 113.28 |
| 2010 | 117.91 | 119.94 | 127.53 | 122.31 | 108.73 | 106.40 | 102.84 | 102.63 | 109.95 | 112.16 | 116.17 | 122.73 |
| 2011 | 121.53 | 124.28 | 123.35 | 127.79 | 134.24 | 129.26 | 128.19 | 119.36 | 118.28 | 125.67 | 127.48 | 134.59 |
| 2012 | 142.42 | 143.99 | 149.51 | 150.29 | 150.07 | 159.07 | 160.74 | 160.74 | 165.47 | 156.93 | 161.34 | 158.92 |
| 2013 | 168.92 | 178.11 | 191.91 | 198.41 | 209.10 | 202.53 | 225.87 | 223.66 | 233.45 | 225.66 | 246.67 | 246.79 |
| 2014 | 263.91 | 277.13 | 262.34 | 247.80 | 260.99 | 274.87 | 276.25 | 296.82 | 304.03 | 326.16 | 338.66 | 352.48 |
| 2015 | 391.34 | 419.34 | 448.65 | 421.01 | 463.44 | 456.29 | 476.60 | 424.39 | 370.76 | 401.72 | 430.21 | 423.32 |
| 2016 | 345.01 | 326.39 | 325.66 | 342.05 | 366.15 | 355.48 | 389.06 | 378.89 | 385.50 | 340.52 | 369.37 | 372.46 |
| 2017 | 391.88 | 436.08 | 454.95 | 456.28 | 415.30 | 455.96 | 449.05 | 468.44 | 473.40 | 468.37 | 491.88 | 501.07 |
| 2018 | 535.61 | 535.64 | 525.88 | 523.61 | 556.39 | | | | | | | |

| IC1 (EUR) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|--------|-------|-------|--------|--------|--------|------|-------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | 0.75 | 4.41 | 2.17 | 0.33 | -6.34 | 4.66 | 7.17 | 13.28 |
| 2010 | 4.09 | 1.72 | 6.33 | -4.09 | -11.10 | -2.14 | -3.35 | -0.20 | 7.13 | 2.01 | 3.58 | 5.65 | 8.34 |
| 2011 | -0.98 | 2.26 | -0.75 | 3.60 | 5.05 | -3.71 | -0.83 | -6.89 | -0.90 | 6.25 | 1.44 | 5.58 | 9.66 |
| 2012 | 5.82 | 1.10 | 3.83 | 0.52 | -0.15 | 6.00 | 1.05 | 0.00 | 2.94 | -5.16 | 2.81 | -1.50 | 18.08 |
| 2013 | 6.29 | 5.44 | 7.75 | 3.39 | 5.39 | -3.14 | 11.52 | -0.98 | 4.38 | -3.34 | 9.31 | 0.05 | 55.29 |
| 2014 | 6.94 | 5.01 | -5.34 | -5.54 | 5.32 | 5.32 | 0.50 | 7.45 | 2.43 | 7.28 | 3.83 | 4.08 | 42.83 |
| 2015 | 11.02 | 7.15 | 6.99 | -6.16 | 10.08 | -1.54 | 4.45 | -10.95 | -12.64 | 8.35 | 7.09 | -1.60 | 20.10 |
| 2016 | -18.50 | -5.40 | -0.22 | 5.03 | 7.05 | -2.91 | 9.45 | -2.61 | 1.74 | -11.67 | 8.47 | 0.84 | -12.01 |
| 2017 | 5.21 | 11.28 | 4.33 | 0.29 | -8.98 | 9.79 | -1.52 | 4.32 | 1.06 | -1.06 | 5.02 | 1.87 | 34.53 |
| 2018 | 6.89 | 0.01 | -1.82 | -0.43 | 6.26 | | | | | | | | 11.04 |

| IC2 (SEK) NAV | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |
| 2013 | 105.95 | 109.53 | 117.11 | 123.34 | 131.02 | 128.83 | 142.56 | 142.09 | 147.55 | 144.39 | 159.03 | 158.77 |
| 2014 | 169.27 | 178.14 | 170.53 | 162.83 | 172.56 | 182.30 | 184.56 | 197.44 | 201.10 | 218.77 | 227.47 | 240.91 |
| 2015 | 264.32 | 283.76 | 300.86 | 285.57 | 313.96 | 305.90 | 326.08 | 292.97 | 252.07 | 273.89 | 288.10 | 281.94 |
| 2016 | 232.96 | 221.76 | 219.09 | 228.93 | 248.02 | 243.80 | 270.79 | 263.91 | 270.85 | 245.87 | 263.97 | 260.88 |
| 2017 | 270.49 | 305.07 | 315.32 | 318.79 | 292.29 | 318.16 | 310.91 | 322.70 | 331.45 | 331.49 | 352.83 | 356.33 |
| 2018 | 379.63 | 389.78 | 388.65 | 395.52 | 411.90 | | | | | | | |

| IC2 (SEK) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|-------|-------|-------|--------|--------|-------|-------|-------|-------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2013 | 5.95 | 3.38 | 6.92 | 5.32 | 6.23 | -1.67 | 10.66 | -0.33 | 3.84 | -2.14 | 10.14 | -0.16 | 58.77 |
| 2014 | 6.61 | 5.24 | -4.27 | -4.52 | 5.98 | 5.64 | 1.24 | 6.98 | 1.85 | 8.79 | 3.98 | 5.91 | 51.74 |
| 2015 | 9.72 | 7.35 | 6.03 | -5.08 | 9.94 | -2.57 | 6.60 | -10.15 | -13.96 | 8.66 | 5.19 | -2.14 | 17.03 |
| 2016 | -17.37 | -4.81 | -1.20 | 4.49 | 8.34 | -1.70 | 11.07 | -2.54 | 2.63 | -9.22 | 7.36 | -1.17 | -7.47 |
| 2017 | 3.68 | 12.78 | 3.36 | 1.10 | -7.69 | 8.11 | -2.28 | 3.79 | 2.71 | 0.01 | 6.44 | 0.99 | 36.59 |
| 2018 | 6.54 | 2.67 | -0.29 | 1.77 | 4.14 | | | | | | | | 15.60 |

| IC1 (USD) NAV | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |
| 2015 | | 106.43 | 109.37 | 107.12 | 114.84 | 114.48 | 118.78 | 107.70 | 93.74 | 100.50 | 102.88 | 104.09 |
| 2016 | 84.51 | 80.27 | 84.02 | 88.68 | 92.24 | 89.25 | 98.50 | 95.48 | 98.04 | 84.48 | 88.63 | 88.85 |
| 2017 | 95.78 | 104.78 | 110.08 | 112.50 | 105.65 | 116.97 | 118.72 | 124.26 | 125.01 | 121.84 | 130.74 | 133.94 |
| 2018 | 147.42 | 145.05 | 143.28 | 140.20 | 145.38 | | | | | | | |

| IC1 (USD) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|-------|-------|-------|-------|--------|--------|------|------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2015 | | 6.43 | 2.76 | -2.06 | 7.21 | -0.31 | 3.76 | -9.33 | -12.96 | 7.21 | 2.37 | 1.18 | 4.09 |
| 2016 | -18.81 | -5.02 | 4.67 | 5.55 | 4.01 | -3.24 | 10.36 | -3.07 | 2.68 | -13.83 | 4.91 | 0.25 | -14.64 |
| 2017 | 7.80 | 9.40 | 5.06 | 2.20 | -6.09 | 10.71 | 1.50 | 4.67 | 0.60 | -2.54 | 7.30 | 2.45 | 50.75 |
| 2018 | 10.06 | -1.61 | -1.22 | -2.15 | 3.69 | | | | | | | | 8.54 |

| IC2 (USD) NAV | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC |
| 2014 | | | | | 102.92 | 108.60 | 106.82 | 113.71 | 112.69 | 120.10 | 124.21 | 126.40 |
| 2015 | 132.75 | 141.32 | 145.96 | 143.02 | 153.38 | 152.95 | 158.76 | 143.26 | 124.74 | 133.79 | 137.03 | 138.70 |
| 2016 | 112.66 | 107.07 | 112.12 | 118.40 | 123.21 | 119.27 | 131.69 | 127.71 | 131.20 | 113.12 | 118.73 | 119.08 |
| 2017 | 128.42 | 140.54 | 147.72 | 151.02 | 141.89 | 156.98 | 159.38 | 166.89 | 167.94 | 163.77 | 175.76 | 180.12 |
| 2018 | 198.33 | 195.19 | 192.99 | 188.92 | 195.95 | | | | | | | |

| IC2 (USD) PERFORMANCE %. NET OF FEES | | | | | | | | | | | | | |
|--------------------------------------|--------|-------|-------|-------|-------|-------|-------|-------|--------|--------|------|------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2014 | | | | | 2.92 | 5.52 | -1.64 | 6.45 | -0.90 | 6.58 | 3.42 | 1.76 | 26.40 |
| 2015 | 5.02 | 6.46 | 3.28 | -2.01 | 7.24 | -0.28 | 3.80 | -9.76 | -12.93 | 7.26 | 2.42 | 1.22 | 9.73 |
| 2016 | -18.77 | -4.96 | 4.72 | 5.60 | 4.06 | -3.20 | 10.41 | -3.02 | 2.73 | -13.78 | 4.96 | 0.29 | -14.15 |
| 2017 | 7.84 | 9.44 | 5.11 | 2.23 | -6.05 | 10.63 | 1.53 | 4.71 | 0.63 | -2.48 | 7.32 | 2.48 | 51.26 |
| 2018 | 10.11 | -1.58 | -1.13 | -2.11 | 3.72 | | | | | | | | 8.79 |

| IC3 (EUR) NAV | | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | |
| 2009 | | | | | | | | 102.15 | 103.33 | 96.78 | 101.30 | 109.19 | |
| 2010 | 114.20 | 116.43 | 124.73 | 119.62 | 106.33 | 104.06 | 100.57 | 100.37 | 107.52 | 109.68 | 113.59 | 120.00 | |
| 2011 | 118.82 | 121.50 | 120.59 | 124.92 | 131.89 | 126.43 | 125.36 | 116.73 | 115.66 | 122.76 | 124.53 | 132.03 | |
| 2012 | 140.67 | 142.42 | 148.58 | 149.43 | 149.16 | 159.24 | 161.09 | 161.06 | 166.38 | 157.79 | 162.21 | 159.79 | |
| 2013 | 170.25 | 180.70 | 196.39 | 203.85 | 216.23 | 208.50 | 235.66 | 233.03 | 244.50 | 236.34 | 260.09 | 260.40 | |
| 2014 | 280.76 | 296.58 | 279.47 | 263.97 | 278.02 | 294.48 | 296.09 | 321.00 | 329.83 | 356.89 | 372.31 | 389.50 | |
| 2015 | 437.99 | 471.80 | 508.68 | 477.10 | 527.32 | 518.14 | 544.00 | 481.68 | 420.82 | 455.95 | 488.29 | 480.47 | |
| 2016 | 391.59 | 370.46 | 369.62 | 388.23 | 415.58 | 403.47 | 441.58 | 430.05 | 437.55 | 386.50 | 419.24 | 422.75 | |
| 2017 | 444.79 | 494.96 | 516.44 | 518.14 | 471.42 | 517.72 | 509.84 | 533.67 | 539.99 | 534.17 | 563.68 | 575.38 | |
| 2018 | 620.04 | 620.31 | 607.45 | 604.83 | 647.20 | | | | | | | | |

| IC3 (EUR) PERFORMANCE %. NET OF FEES | | | | | | | | | | | | | |
|--------------------------------------|--------|-------|-------|-------|--------|-------|-------|--------|--------|--------|-------|-------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | | | 2.15 | 1.16 | -6.34 | 4.67 | 7.79 | 9.19 |
| 2010 | 4.59 | 1.95 | 7.13 | -4.10 | -11.11 | -2.13 | -3.35 | -0.20 | 7.12 | 2.01 | 3.56 | 5.64 | 9.90 |
| 2011 | -0.98 | 2.26 | -0.75 | 3.59 | 5.58 | -4.14 | -0.85 | -6.88 | -0.92 | 6.14 | 1.44 | 6.02 | 10.03 |
| 2012 | 6.54 | 1.24 | 4.33 | 0.57 | -0.18 | 6.76 | 1.16 | -0.02 | 3.30 | -5.16 | 2.80 | -1.49 | 21.03 |
| 2013 | 6.55 | 6.14 | 8.68 | 3.80 | 6.07 | -3.57 | 13.03 | -1.12 | 4.92 | -3.34 | 10.05 | 0.12 | 62.96 |
| 2014 | 7.82 | 5.63 | -5.77 | -5.55 | 5.32 | 5.92 | 0.55 | 8.41 | 2.75 | 8.20 | 4.32 | 4.62 | 49.58 |
| 2015 | 12.45 | 7.72 | 7.82 | -6.21 | 10.53 | -1.74 | 4.99 | -11.46 | -12.63 | 8.35 | 7.09 | -1.60 | 23.36 |
| 2016 | -18.50 | -5.40 | -0.23 | 5.03 | 7.04 | -2.91 | 9.45 | -2.61 | 1.74 | -11.67 | 8.47 | 0.84 | -12.01 |
| 2017 | 5.21 | 11.28 | 4.34 | 0.33 | -9.02 | 9.82 | -1.52 | 4.67 | 1.18 | -1.08 | 5.52 | 2.08 | 36.10 |
| 2018 | 7.76 | 0.04 | -2.07 | -0.43 | 7.01 | | | | | | | | 12.48 |

| ID1 (SEK) NAV | | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | |
| 2012 | | | | | 100.64 | 104.51 | 101.00 | 100.77 | 105.42 | 101.93 | 105.47 | 103.07 | |
| 2013 | 109.66 | 109.21 | 116.69 | 122.83 | 130.33 | 127.88 | 141.46 | 140.87 | 146.24 | 143.04 | 157.52 | 157.19 | |
| 2014 | 167.54 | 168.39 | 161.54 | 154.18 | 163.36 | 172.51 | 174.59 | 186.71 | 190.10 | 206.73 | 214.90 | 227.49 | |
| 2015 | 249.52 | 256.41 | 271.30 | 257.41 | 282.93 | 275.68 | 293.76 | 263.61 | 226.72 | 246.24 | 258.91 | 253.27 | |
| 2016 | 209.19 | 186.39 | 184.08 | 192.27 | 208.21 | 204.58 | 227.14 | 221.28 | 227.01 | 205.99 | 221.08 | 218.41 | |
| 2017 | 226.36 | 247.58 | 257.17 | 259.92 | 239.81 | 259.22 | 253.21 | 262.73 | 269.78 | 269.72 | 287.00 | 289.42 | |
| 2018 | 308.23 | 298.96 | 297.90 | 303.06 | 315.52 | | | | | | | | |

| ID1 (SEK) PERFORMANCE %. NET OF FEES | | | | | | | | | | | | | |
|--------------------------------------|--------|--------|-------|-------|-------|-------|-------|--------|--------|-------|-------|-------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2012 | | | | | 0.64 | 3.85 | -3.36 | -0.23 | 4.61 | -3.31 | 3.47 | -2.28 | 3.07 |
| 2013 | 6.39 | -0.41 | 6.85 | 5.26 | 6.11 | -1.88 | 10.62 | -0.42 | 3.81 | -2.19 | 10.12 | -0.21 | 52.51 |
| 2014 | 6.58 | 0.51 | -4.07 | -4.56 | 5.95 | 5.60 | 1.21 | 6.94 | 1.82 | 8.75 | 3.95 | 5.86 | 44.72 |
| 2015 | 9.68 | 2.76 | 5.81 | -5.12 | 9.91 | -2.56 | 6.56 | -10.26 | -13.99 | 8.61 | 5.15 | -2.18 | 11.33 |
| 2016 | -17.40 | -10.90 | -1.24 | 4.45 | 8.29 | -1.74 | 11.03 | -2.58 | 2.59 | -9.26 | 7.33 | -1.21 | -13.76 |
| 2017 | 3.64 | 9.37 | 3.87 | 1.07 | -7.74 | 8.09 | -2.32 | 3.76 | 2.68 | -0.02 | 6.41 | 0.84 | 32.51 |
| 2018 | 6.50 | -3.01 | -0.35 | 1.73 | 4.11 | | | | | | | | 9.02 |

| RC1 (EUR) NAV | | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | |
| 2010 | | | | | | | | | 104.35 | 104.75 | 110.36 | 115.32 | |
| 2011 | 114.18 | 116.50 | 115.79 | 119.40 | 125.10 | 120.47 | 119.15 | 110.91 | 109.86 | 116.68 | 118.31 | 124.92 | |
| 2012 | 132.14 | 133.59 | 138.66 | 139.34 | 139.09 | 147.39 | 148.89 | 148.83 | 153.16 | 145.20 | 149.21 | 146.92 | |
| 2013 | 156.14 | 164.59 | 177.28 | 183.22 | 192.89 | 185.65 | 206.96 | 204.86 | 212.69 | 205.49 | 224.58 | 224.79 | |
| 2014 | 240.30 | 251.66 | 236.42 | 223.21 | 235.00 | 247.45 | 248.60 | 266.95 | 273.34 | 293.13 | 304.24 | 315.14 | |
| 2015 | 349.47 | 373.47 | 398.19 | 373.48 | 411.03 | 404.45 | 422.31 | 375.75 | 328.13 | 355.37 | 380.41 | 374.15 | |
| 2016 | 304.81 | 288.23 | 287.45 | 301.80 | 322.91 | 313.37 | 342.82 | 333.71 | 339.38 | 299.66 | 324.90 | 327.48 | |
| 2017 | 344.40 | 383.08 | 399.53 | 400.83 | 364.36 | 400.14 | 393.87 | 411.29 | 415.46 | 410.84 | 431.35 | 439.53 | |
| 2018 | 469.64 | 469.79 | 461.25 | 459.04 | 487.65 | | | | | | | | |

| RC1 (EUR) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|-------|-------|-------|--------|--------|--------|------|-------|--------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2010 | | | | | | | | | 4.35 | 0.38 | 5.36 | 4.49 | 15.32 |
| 2011 | -0.99 | 2.03 | -0.61 | 3.12 | 4.77 | -3.70 | -1.10 | -6.92 | -0.95 | 6.21 | 1.40 | 5.59 | 8.32 |
| 2012 | 5.78 | 1.10 | 3.80 | 0.49 | -0.18 | 5.97 | 1.02 | -0.04 | 2.91 | -5.20 | 2.76 | -1.53 | 17.61 |
| 2013 | 6.28 | 5.41 | 7.71 | 3.35 | 5.28 | -3.75 | 11.48 | -1.01 | 3.82 | -3.39 | 9.29 | 0.09 | 53.00 |
| 2014 | 6.90 | 4.73 | -6.06 | -5.59 | 5.28 | 5.30 | 0.46 | 7.38 | 2.39 | 7.24 | 3.80 | 3.58 | 40.19 |
| 2015 | 10.89 | 6.87 | 6.62 | -6.21 | 10.05 | -1.60 | 4.42 | -11.03 | -12.67 | 8.30 | 7.05 | -1.65 | 18.73 |
| 2016 | -18.53 | -5.44 | -0.27 | 4.99 | 6.99 | -2.95 | 9.40 | -2.66 | 1.70 | -11.70 | 8.42 | 0.79 | -12.47 |
| 2017 | 5.17 | 11.23 | 4.29 | 0.33 | -9.10 | 9.82 | -1.57 | 4.42 | 1.01 | -1.11 | 4.99 | 1.90 | 34.22 |
| 2018 | 6.85 | 0.03 | -1.82 | -0.48 | 6.23 | | | | | | | | 10.95 |

| RC1 (SEK) NAV | | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | 99.74 | 99.92 | 101.00 | 101.51 | 96.72 | 101.85 | 106.75 | |
| 2010 | 110.70 | 108.05 | 115.09 | 109.18 | 96.69 | 93.87 | 89.69 | 88.93 | 93.37 | 96.59 | 98.29 | 102.16 | |
| 2011 | 98.91 | 100.22 | 101.80 | 105.28 | 111.04 | 109.04 | 107.03 | 100.09 | 100.29 | 104.24 | 106.42 | 111.05 | |
| 2012 | 118.78 | 118.87 | 123.79 | 125.05 | 125.79 | 130.61 | 126.17 | 125.85 | 131.65 | 127.25 | 131.60 | 128.55 | |
| 2013 | 136.76 | 141.24 | 150.89 | 158.78 | 168.47 | 165.25 | 182.72 | 181.89 | 188.61 | 184.41 | 203.02 | 202.38 | |
| 2014 | 215.63 | 226.61 | 216.26 | 206.33 | 218.55 | 230.73 | 233.43 | 249.55 | 253.98 | 276.09 | 286.74 | 302.97 | |
| 2015 | 332.20 | 356.11 | 376.45 | 357.02 | 392.32 | 381.98 | 406.89 | 365.09 | 313.86 | 340.74 | 358.11 | 350.16 | |
| 2016 | 289.10 | 274.97 | 271.43 | 283.40 | 306.76 | 301.29 | 334.38 | 325.60 | 333.90 | 302.85 | 324.90 | 320.85 | |
| 2017 | 332.37 | 374.59 | 388.12 | 392.14 | 361.60 | 390.79 | 381.55 | 395.80 | 406.28 | 406.01 | 431.88 | 435.88 | |
| 2018 | 464.01 | 476.10 | 474.20 | 482.24 | 501.86 | | | | | | | | |

| RC1 (SEK) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|--------|-------|-------|--------|--------|-------|-------|-------|-------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | -0.26 | 0.18 | 1.08 | 0.50 | -4.72 | 5.30 | 4.81 | 6.75 |
| 2010 | 3.70 | -2.39 | 6.52 | -5.14 | -11.44 | -2.92 | -4.45 | -0.85 | 4.99 | 3.45 | 1.76 | 3.94 | -4.30 |
| 2011 | -3.18 | 1.32 | 1.58 | 3.42 | 5.47 | -1.80 | -1.84 | -6.48 | 0.20 | 3.94 | 2.09 | 4.35 | 8.70 |
| 2012 | 6.96 | 0.08 | 4.14 | 1.02 | 0.59 | 3.83 | -3.40 | -0.25 | 4.61 | -3.34 | 3.42 | -2.32 | 15.76 |
| 2013 | 6.39 | 3.28 | 6.83 | 5.23 | 6.10 | -1.91 | 10.57 | -0.45 | 3.69 | -2.23 | 10.09 | -0.32 | 57.43 |
| 2014 | 6.55 | 5.09 | -4.57 | -4.59 | 5.92 | 5.57 | 1.17 | 6.91 | 1.78 | 8.71 | 3.86 | 5.66 | 49.70 |
| 2015 | 9.65 | 7.20 | 5.71 | -5.16 | 9.89 | -2.64 | 6.52 | -10.27 | -14.03 | 8.56 | 5.10 | -2.22 | 15.58 |
| 2016 | -17.44 | -4.89 | -1.29 | 4.41 | 8.24 | -1.78 | 10.98 | -2.63 | 2.55 | -9.30 | 7.28 | -1.25 | -8.37 |
| 2017 | 3.59 | 12.70 | 3.61 | 1.04 | -7.79 | 8.07 | -2.36 | 3.73 | 2.65 | -0.07 | 6.37 | 0.93 | 35.85 |
| 2018 | 6.45 | 2.61 | -0.40 | 1.70 | 4.07 | | | | | | | | 15.14 |

| RC2 (SEK) NAV | | | | | | | | | | | | | |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | 99.74 | 99.98 | 101.12 | 101.68 | 96.94 | 102.10 | 107.07 | |
| 2010 | 111.07 | 108.57 | 115.69 | 109.78 | 97.28 | 94.47 | 90.31 | 89.58 | 94.10 | 97.38 | 99.14 | 103.08 | |
| 2011 | 99.84 | 101.20 | 102.84 | 106.40 | 112.28 | 110.30 | 108.32 | 101.33 | 101.58 | 105.64 | 107.89 | 112.63 | |
| 2012 | 120.30 | 120.44 | 125.51 | 126.83 | 127.66 | 132.58 | 128.13 | 127.86 | 133.77 | 129.36 | 133.84 | 130.80 | |
| 2013 | 139.17 | 143.74 | 153.48 | 161.57 | 171.53 | 167.92 | 185.74 | 185.04 | 192.06 | 187.86 | 206.87 | 206.39 | |
| 2014 | 219.98 | 231.28 | 221.05 | 210.98 | 223.54 | 236.05 | 238.90 | 255.47 | 260.24 | 283.00 | 293.97 | 310.92 | |
| 2015 | 341.02 | 365.80 | 386.77 | 366.96 | 403.34 | 392.85 | 418.61 | 375.87 | 323.26 | 351.09 | 369.14 | 361.10 | |
| 2016 | 298.25 | 283.80 | 280.26 | 292.73 | 317.00 | 311.48 | 345.83 | 336.89 | 345.62 | 313.62 | 336.59 | 332.52 | |
| 2017 | 344.62 | 388.54 | 402.06 | 406.34 | 374.90 | 405.23 | 395.81 | 410.70 | 421.71 | 421.61 | 448.59 | 452.80 | |
| 2018 | 482.21 | 495.26 | 493.58 | 502.12 | 522.72 | | | | | | | | |

| RC2 (SEK) PERFORMANCE % NET OF FEES | | | | | | | | | | | | | |
|-------------------------------------|--------|-------|-------|-------|--------|-------|-------|--------|--------|-------|-------|-------|-------|
| YEAR | JAN | FEB | MAR | APR | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | TOTAL |
| 2009 | | | | | | -0.26 | 0.24 | 1.14 | 0.55 | -4.66 | 5.32 | 4.87 | 7.07 |
| 2010 | 3.74 | -2.25 | 6.56 | -5.11 | -11.39 | -2.89 | -4.40 | -0.81 | 5.05 | 3.49 | 1.81 | 3.97 | -3.73 |
| 2011 | -3.14 | 1.36 | 1.62 | 3.46 | 5.53 | -1.76 | -1.80 | -6.45 | 0.25 | 4.00 | 2.13 | 4.39 | 9.26 |
| 2012 | 6.81 | 0.12 | 4.21 | 1.05 | 0.65 | 3.85 | -3.36 | -0.21 | 4.62 | -3.30 | 3.46 | -2.27 | 16.13 |
| 2013 | 6.40 | 3.28 | 6.78 | 5.27 | 6.16 | -2.10 | 10.61 | -0.38 | 3.79 | -2.19 | 10.12 | -0.23 | 57.79 |
| 2014 | 6.58 | 5.14 | -4.42 | -4.56 | 5.95 | 5.60 | 1.21 | 6.94 | 1.87 | 8.75 | 3.88 | 5.77 | 50.65 |
| 2015 | 9.68 | 7.27 | 5.73 | -5.12 | 9.91 | -2.60 | 6.56 | -10.21 | -14.00 | 8.61 | 5.14 | -2.18 | 16.14 |
| 2016 | -17.41 | -4.84 | -1.25 | 4.45 | 8.29 | -1.74 | 11.03 | -2.59 | 2.59 | -9.26 | 7.32 | -1.21 | -7.91 |
| 2017 | 3.64 | 12.74 | 3.48 | 1.06 | -7.74 | 8.09 | -2.32 | 3.76 | 2.68 | -0.02 | 6.40 | 0.94 | 36.17 |
| 2018 | 6.50 | 2.71 | -0.34 | 1.73 | 4.10 | | | | | | | | 15.44 |

ABOUT RHENMAN & PARTNERS

Rhenman & Partners Asset Management, founded in 2008, is a Stockholm-based investment manager focusing on two niche funds administered by SEB Fund Services S.A.: Rhenman Healthcare Equity L/S, founded in 2009, and Rhenman Global Opportunities L/S, founded in 2016. Assets under management amount to approximately EUR 600m. Investment Teams of both Funds are in their investment processes supported by renowned Advisory Boards, including professors and experts with many years of market experience and extensive networks around the world.

LEGAL DISCLAIMER

Rhenman Healthcare Equity L/S. "The Fund" is not an investment fund as defined in the European Union directives relating to undertakings for collective investment in transferable securities (UCITS). Legal information regarding Fund is contained in the Prospectus and the KIID, available at Rhenman & Partners Asset Management AB (Rhenman & Partners) webpage: <http://rhepa.com/the-fund/prospectus/>.

This material has been prepared by Rhenman & Partners for professional and non-professional investors. Rhenman & Partners when preparing this information has not taken into account any one customer's particular investment objectives, financial resources or other relevant circumstances and the opinions and recommendations herein are not intended to represent recommendations of particular investments to particular customers. This material is for informational purposes only and should not be construed as an offer or solicitation to sell or buy units of the Fund. Investors is strongly recommended to get professional advice as to whether investment in the Fund is appropriate having regard to their particular investment needs, objectives and financial circumstances, before investing.

All securities' transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk. There can be no assurance that an investment in the Fund will achieve profits or avoid incurring substantial losses. There is a high degree of risk inherent in investments and they may not be suitable for all eligible investors. It is possible that an investor may lose some or all of its investment. The past is not necessarily a guide to the future performance of an investment. The value of investments may fall as well as rise and investors may not get back the amount invested. Changes in rates of foreign exchange may cause the value of investments to go up or down.

Before making an investment decision, an investor and/or its adviser should (i) consider the suitability of investments in the Fund with respect to its investment objectives and personal situation and (ii) consider factors such as its personal net worth, income, age, risk tolerance and liquidity needs. Short-term investors and investors who cannot bear the loss of some or all of their investment or the risks associated with the limited liquidity of an investment should not invest.

Due care and attention has been used in the preparation of this information. However, actual results may vary from their forecasts, and any variation may be materially positive or negative. Forecasts, by their very nature, are subject to uncertainty and contingencies, many of which are outside the control of Rhenman & Partners. Rhenman & Partners cannot guarantee that the information contained herein is without fault or entirely accurate. There may be delays, omissions or inaccuracies in the information. Any dated information is published as of its date only and no obligation or responsibility is undertaken to update or amend any such information.

The information in this material is based on sources that Rhenman & Partners believes to be reliable. Rhenman & Partners can however not guarantee that all information is correct. Furthermore, information and opinions may change without notice. Rhenman & Partners is under no obligation to make amendments or changes to this publication if errors are found or opinions or information change. Rhenman & Partners accepts no responsibility for the accuracy of its sources.

Rhenman & Partners is the owner of all works of authorship including, but not limited to, all design text, images and trademarks in this material unless otherwise explicitly stated. The use of Rhenman & Partners' material, works or trademarks is forbidden without written consent except where otherwise expressly stated. Furthermore, it is prohibited to publish material made or gathered by Rhenman & Partners without written consent.

By accessing and using the <http://rhepa.com/> website and any pages thereof, you acknowledge that you have reviewed the following important legal information and understand and agree to the terms and conditions set therein. If you do not agree to the terms and conditions in this disclaimer, do not access or use <http://rhepa.com/website> in any way.

Products and services described herein are not available to all persons in all geographical locations. Rhenman & Partner will not provide any such products or services to any person if the provision of such services could be in violation of law or regulation in such person's home country jurisdiction or any other related jurisdiction. The units of the Fund may not be offered or sold to or within the United States or in any other country where such offer or sale would conflict with applicable laws or regulations.

In no event, including (but not limited to) negligence, will Rhenman & Partner be liable to you or anyone else for any consequential, incidental, special or indirect damages (including but not limited to lost profits, trading losses and damages).

The sole legally binding basis for the purchase of shares of the Fund described in this information is the latest valid sales prospectus with its terms of contract. Subscriptions cannot be received on the basis of financial reports.

An investment in the Fund does not represent deposits or other liabilities of any member of the Rhenman & Partners Group. Neither Rhenman & Partners nor any member of the Rhenman & Partners Group and its affiliates guarantees in any way the performance of the Fund, repayment of capital from the Fund, any particular return from or any increase in the value of the Fund.

SUBSCRIBE TO OUR MONTHLY NEWSLETTER AT WWW.RHEPA.COM

CONTACT DETAILS

Rhenman & Partners
 Asset Management AB
 Strandvägen 5A
 114 51 Stockholm, Sweden
 Tel + 46 8 459 88 80
info@rhepa.com

International investors (non Swedish):
 Carl Grevelius
 Head of Investor Relations
 Tel + 46 8 459 88 83
carl@rhepa.com

Swedish investors:
 Anders Grelsson
 Swedish Investor Relations
 Mob + 46 70 374 43 20
anders@rhepa.com

WWW.RHEPA.COM